PH12015502302A1 - Treatment of allergic rhinitis using a combination of mometasone and olopatadine - Google Patents

Treatment of allergic rhinitis using a combination of mometasone and olopatadine

Info

Publication number
PH12015502302A1
PH12015502302A1 PH12015502302A PH12015502302A PH12015502302A1 PH 12015502302 A1 PH12015502302 A1 PH 12015502302A1 PH 12015502302 A PH12015502302 A PH 12015502302A PH 12015502302 A PH12015502302 A PH 12015502302A PH 12015502302 A1 PH12015502302 A1 PH 12015502302A1
Authority
PH
Philippines
Prior art keywords
olopatadine
mometasone
combination
allergic rhinitis
treatment
Prior art date
Application number
PH12015502302A
Other languages
English (en)
Other versions
PH12015502302B1 (en
Inventor
Khairatkar Joshi Neelima
kulkarni Abhay
Wale Dinesh Pradeep
Bhosale Vikram Mansingh
Agarwal Piyush
Keohane Patrick
Sudeesh K Tantry
Oh Chad
Original Assignee
Glenmark Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Ltd filed Critical Glenmark Pharmaceuticals Ltd
Publication of PH12015502302B1 publication Critical patent/PH12015502302B1/en
Publication of PH12015502302A1 publication Critical patent/PH12015502302A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PH12015502302A 2013-10-04 2015-10-05 Treatment of allergic rhinitis using a combination of mometasone and olopatadine PH12015502302A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3174MU2013 2013-10-04
PCT/IB2014/065035 WO2015049665A1 (en) 2013-10-04 2014-10-03 Treatment of allergic rhinitis using a combination of mometasone and olopatadine

Publications (2)

Publication Number Publication Date
PH12015502302B1 PH12015502302B1 (en) 2016-02-15
PH12015502302A1 true PH12015502302A1 (en) 2016-02-15

Family

ID=51982657

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12015502302A PH12015502302A1 (en) 2013-10-04 2015-10-05 Treatment of allergic rhinitis using a combination of mometasone and olopatadine

Country Status (21)

Country Link
US (1) US10646500B2 (enExample)
EP (2) EP2922553B1 (enExample)
JP (3) JP6419195B2 (enExample)
CN (2) CN112773808A (enExample)
ES (1) ES3071407T3 (enExample)
FI (1) FI2922553T3 (enExample)
HK (1) HK1215674A1 (enExample)
HR (1) HRP20260742T1 (enExample)
LT (1) LT2922553T (enExample)
MX (2) MX2015009429A (enExample)
MY (1) MY176808A (enExample)
PH (1) PH12015502302A1 (enExample)
PL (1) PL2922553T3 (enExample)
PT (1) PT2922553T (enExample)
RS (1) RS68262B1 (enExample)
RU (1) RU2686670C2 (enExample)
SI (1) SI2922553T1 (enExample)
SM (1) SMT202600244T1 (enExample)
UA (1) UA120587C2 (enExample)
WO (1) WO2015049665A1 (enExample)
ZA (1) ZA201504740B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
MX2015009429A (es) * 2013-10-04 2015-10-09 Glenmark Pharmaceuticals Ltd Tratamiento de rinitis alergica utilizando una combinacion de mometasona y olopatadina.
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
CN115444851A (zh) * 2017-06-28 2022-12-09 格兰马克专业公司 用于治疗鼻炎的分配装置和药物组合物
CN111787954B (zh) * 2018-02-23 2023-09-05 格兰马克专业公司 使用莫美他松和奥洛他定的组合治疗儿科受试者的过敏性鼻炎
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
US4923892A (en) 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
EP1227812B1 (en) 1999-10-08 2007-04-18 Schering Corporation Topical nasal treatment using desloratadine and mometasone furoate
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
CA2504200A1 (en) * 2002-11-12 2004-05-27 Alcon, Inc. The use of an anti-allergy agent and a steroid to treat allergic rhinitis
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
PL1814538T3 (pl) 2004-11-24 2010-02-26 Alcon Inc Sposób dostarczania donosowego sprayu
PT1919450E (pt) * 2005-09-01 2014-09-10 Meda Ab Composição lipossomal contendo anti-histamínico e corticosteróide e sua utilização para a preparação de um medicamento para o tratamento de rinite e distúrbios relacionados
EP1968548A2 (en) 2005-12-02 2008-09-17 Elan Pharma International Limited Mometasone compositions and methods of making and using the same
RU2434652C2 (ru) 2006-04-21 2011-11-27 Токо Якухин Когио Кабусики Кайся Емкость для текучей среды и система безвоздушного дозирования текучей среды с использованием упомянутой емкости
JP2010531898A (ja) * 2007-06-28 2010-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド 鼻および眼へのコルチコステロイド水溶液送達
EP2318049A1 (en) * 2008-07-15 2011-05-11 Schering Corporation Intranasal compositions comprising a decongestant and a corticosteroid
US8642069B2 (en) 2008-08-27 2014-02-04 Alexander D. Goldin Composition and method for treating colds
BR112012001169A2 (pt) 2009-07-17 2016-03-01 Alcon Res Ltd sistema de pulverização nasal de olopatadina para crianças
CN102078326A (zh) * 2009-11-26 2011-06-01 天津金耀集团有限公司 含有聚维酮碘与糠酸莫米松的局部使用组合物
CN102078285A (zh) * 2009-11-26 2011-06-01 天津金耀集团有限公司 含有皮质激素和h1受体拮抗剂的鼻用原位凝胶
WO2011141929A2 (en) 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
JP5683719B2 (ja) 2011-01-04 2015-03-11 イスタ・ファーマシューティカルズ・インコーポレイテッドIsta Pharmaceuticals,Inc. ベポタスチン組成物
CN104755615A (zh) 2012-10-25 2015-07-01 诺维信公司 用于餐具洗涤的改进的方法
KR20140081925A (ko) 2012-12-12 2014-07-02 한미약품 주식회사 코르티코스테로이드, 항히스타민제 및 스테비아를 포함하는 고미 차폐된 약학 제제
UA116793C2 (uk) 2013-09-13 2018-05-10 Гленмарк Спешіалті С.А. Стабільна фармацевтична композиція з фіксованою дозою, що містить мометазон й олопатадин
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
MX2015009429A (es) * 2013-10-04 2015-10-09 Glenmark Pharmaceuticals Ltd Tratamiento de rinitis alergica utilizando una combinacion de mometasona y olopatadina.

Also Published As

Publication number Publication date
ES3071407T3 (es) 2026-06-23
LT2922553T (lt) 2026-07-10
EP4272839A3 (en) 2024-01-03
RS68262B1 (en) 2026-07-31
WO2015049665A1 (en) 2015-04-09
MY176808A (en) 2020-08-21
JP2018123157A (ja) 2018-08-09
ZA201504740B (en) 2016-10-26
RU2015128496A3 (enExample) 2018-06-19
US20150099725A1 (en) 2015-04-09
PH12015502302B1 (en) 2016-02-15
EP2922553A1 (en) 2015-09-30
SI2922553T1 (sl) 2026-07-31
UA120587C2 (uk) 2020-01-10
PL2922553T3 (pl) 2026-07-13
PT2922553T (pt) 2026-06-05
JP2016531949A (ja) 2016-10-13
HRP20260742T1 (hr) 2026-07-31
CN112773808A (zh) 2021-05-11
JP2020097624A (ja) 2020-06-25
MX2015009429A (es) 2015-10-09
CN105792828A (zh) 2016-07-20
RU2015128496A (ru) 2017-11-13
JP6768733B2 (ja) 2020-10-14
SMT202600244T1 (it) 2026-07-16
US10646500B2 (en) 2020-05-12
RU2019104453A (ru) 2019-03-28
RU2686670C2 (ru) 2019-04-30
FI2922553T3 (fi) 2026-06-15
MX2020003035A (es) 2020-07-22
JP6419195B2 (ja) 2018-11-07
HK1215674A1 (zh) 2016-09-09
EP2922553B1 (en) 2026-05-06
EP4272839A2 (en) 2023-11-08

Similar Documents

Publication Publication Date Title
PH12015502302B1 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
GB201320723D0 (en) Composition and methods of treatment
EP3013407A4 (en) Medical treatment system and method of use
IL242386B (en) Use of Aribolin and Lavetinib as a combination therapy for cancer treatment
IL240169A0 (en) Pyrimidine compositions for use in the treatment of diseases affected by ikke or tbk1 mechanisms
SG195110A1 (en) Pirfenidone and anti-fibrotic therapy in selected patients
MX2015009444A (es) Trampas novedosas en el tratamiento de la degeneracion macular.
EA201600096A1 (ru) Бензил-1н-пиразол[3,4-b]пиридины и их применение
EP3084000A4 (en) Method of diagnosis and treatment
MX2016009306A (es) Reequilibrado inmunologico epicutaneo.
EP2948195A4 (en) INCLUDED DEVICES FOR THE TREATMENT OF MEDICAL WASTE AND METHOD FOR THE USE THEREOF
WO2015197193A3 (en) New use for jnk inhibitor molecules for treatment of various diseases
EA201690997A1 (ru) Композиция для применения в лечении стойкого кашля
WO2015084883A3 (en) Compositions and methods for treating osteoarthritis
EP3066077A4 (en) Treatment of cardiac remodeling and other heart conditions
GB201710822D0 (en) Methods and medical uses relating to the treatment of hypoglycaemia
FI20115165A0 (fi) Terapeuttisia ja diagnostisia menetelmiä
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
GB201708533D0 (en) Improvements in or relating to methods of patient monitoring
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
ZA201600312B (en) Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders
PL3079684T3 (pl) Kompozycje i sposoby do leczenia chorób związanych z układem renina-angiotensyna
EA201591184A1 (ru) Применение пидотимода для лечения атопического дерматита
GB201410954D0 (en) Skin treatment devices and methods
UA136951U (uk) Спосіб і препарат для прискорення консолідації переломів кісток